BAX

Baxter International Inc

Add to Watchlist

Advanced Chart

21.960

+0.2(0.919%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

22.355

Open

21.510

VWAP

21.88

Vol

22.65M

Mkt Cap

11.26B

Low

21.330

Amount

495.55M

EV/EBITDA(TTM)

10.68

Total Shares

509.58M

18.92B

EV/OCF(TTM)

39.76

P/S(TTM)

1.33

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

2.76B

+5.07%

0.594

+7.95%

3.04B

+10.48%

0.713

+22.93%

2.91B

+7.75%

0.639

-20.06%

Estimates Revision

The market is revising Downward the revenue expectations for Baxter International Inc. (BAX) for FY2025, with the revenue forecasts being adjusted by -0.46% over the past three months. During the same period, the stock price has changed by -28.40%.

Revenue Estimates for FY2025

Revise Downward

-0.46%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.89%

In Past 3 Month

Stock Price

Go Down

-28.40%

In Past 3 Month

12 Analyst Rating

63.93% Upside

Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 36.00 USD with a low forecast of 27.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

7 Hold

1 Sell

Hold

63.93% Upside

Current: 21.960

Low

27.00

Averages

36.00

High

42.00

63.93% Upside

Current: 21.960

Low

27.00

Averages

36.00

High

42.00

Morgan Stanley

Underweight

downgrade

$28 -> $27

2025-07-15

Reason

Morgan Stanley

Price Target

$28 -> $27

2025-07-15

downgrade

Underweight

Reason

Morgan Stanley lowered the firm's price target on Baxter to $27 from $28 and keeps an Underweight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.

Citi

Neutral

downgrade

$34 -> $32

2025-07-09

Reason

Citi

Price Target

$34 -> $32

2025-07-09

downgrade

Neutral

Reason

Citi lowered the firm's price target on Baxter to $32 from $34 and keeps a Neutral rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.

Barclays

Matt Miksic

Buy

Maintains

$39 → $41

2025-03-10

Reason

Barclays

Matt Miksic

Price Target

$39 → $41

2025-03-10

Maintains

Buy

Reason

Barclays raised the firm's price target on Baxter to $41 from $39 and keeps an Overweight rating on the shares. The firm updated its model to reflect the company's 2025 guidance and recent commentary.

Goldman Sachs

David Roman

Strong Buy

Initiates

$42

2025-02-26

Reason

Goldman Sachs

David Roman

Price Target

$42

2025-02-26

Initiates

Strong Buy

Reason

Goldman Sachs reinstated coverage of Baxter with a Buy rating and $42 price target. Over the next several quarters, the firm expects the company to make "meaningful progress" toward margin and cash flow improvement, driving its earnings above consensus estimates. Baxter's risk/reward is skewed positively at current levels, the analyst tells investors in a research note.

JP Morgan

Robbie Marcus

Hold

Maintains

$38 → $36

2025-02-21

Reason

JP Morgan

Robbie Marcus

Price Target

$38 → $36

2025-02-21

Maintains

Hold

Reason

Barclays

Matt Miksic

Buy

Initiates

$39

2025-02-20

Reason

Barclays

Matt Miksic

Price Target

$39

2025-02-20

Initiates

Buy

Reason

Barclays reinstated coverage of Baxter with an Overweight rating and $39 price target. The firm updated its sales projections to reflect the company's continuing operations, which exclude sales of renal care in 2024, 2025 and beyond. The analyst believes the macro headwinds facing Baxter are largely discounted at current share levels. The stock's substantial year-to-date underperformance and "significant" deal-related financial flexibility position the shares to outperform relative to the market, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Baxter International Inc (BAX.N) is 8.50, compared to its 5-year average forward P/E of 16.92. For a more detailed relative valuation and DCF analysis to assess Baxter International Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

16.92

Current PE

8.50

Overvalued PE

21.34

Undervalued PE

12.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

12.55

Current EV/EBITDA

9.44

Overvalued EV/EBITDA

14.74

Undervalued EV/EBITDA

10.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.05

Current PS

1.25

Overvalued PS

2.87

Undervalued PS

1.23